Background: The rising prevalence of metabolic syndrome poses a public health challenge, especially in postmenopausal women. Fibrates, including Gemfibrozil, Fenofibrate, and Bezafibrate, show promise in targeting key components of the syndrome, necessitating investigation in this population.

Methods: A parallel-group, three-arm randomized controlled trial enrolled postmenopausal women with metabolic syndrome. Gemfibrozil, Fenofibrate, and Bezafibrate were administered with standardized dosages over 12 weeks. A double-blind approach, placebo use, and ethical considerations ensured robustness.

Results: Baseline characteristics were well-matched, and all three fibrates demonstrated significant improvements in triglycerides, HDL cholesterol, and glucose levels. Gemfibrozil exhibited the most substantial reduction in triglycerides and the highest increase in HDL cholesterol. Statistical significance was observed within each treatment arm (p < 0.05).

Conclusion: Gemfibrozil, Fenofibrate, and Bezafibrate effectively improved metabolic parameters in postmenopausal women with metabolic syndrome. Gemfibrozil emerged as the most beneficial, aligning with previous hypothetical studies. While findings support the potential of fibrates, long-term effects and generalizability to diverse populations warrant further exploration. This study contributes valuable insights into personalized treatment strategies for metabolic syndrome in postmenopausal women.

Keywords: Metabolic syndrome, postmenopausal women, fibrates, lipid profiles.